Four things to know:
1. NVG-291 is a linear peptide comprised of common amino acids.
2. Its Phase 1 safety and pharmacokinetic study in healthy subjects will begin in the first quarter of 2020.
3. The expansion of its Phase 1 trial on spinal cord injury patients will begin in the second half of 2020.
4. A Phase 2 multiple sclerosis trial is set for the first quarter of 2021.
More articles on biologics:
‘A dream come true’: Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker’s spine division stands to gain from 5 acquisitions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
